Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.950-5.350 for the period, compared to the consensus earnings per share estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wells Fargo & Company lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Finally, Piper Sandler upped their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Stock Up 5.0 %

Shares of Halozyme Therapeutics stock traded up $2.57 during trading on Wednesday, reaching $53.76. The company had a trading volume of 2,668,262 shares, compared to its average volume of 1,711,198. The company has a market cap of $6.84 billion, a price-to-earnings ratio of 17.80, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The firm's fifty day moving average is $50.10 and its 200-day moving average is $54.00. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.70% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.